[An observation on antiviral effect of IFN--alpha N1 (Wellferon) in patients with chronic hepatitis B].
In order to observe the antiviral effect of IFN-alpha N1(Wellferon, British Glaxowellcome Company) on CHB, each 50 cases of CHB were selected as the therapy group and the control group. The patients in the therapy group were administrated with 3MU of IFN-alpha N1 once a day for one week, and then 3MU of IFN-alpha N1 three times weekly for 11-23 weeks, whereas the patients in the control group did not receive any antiviral treatment. At 3 months, the serum alanine transaminsae(ALT) was decreased to normal level in 84%(42/50) cases of the therapy group, while only in 46% (23/50) cases of the control group (P < 0.01). The negative seroconversion rate of HBeAg was 56.7% (17/30) and 10.8% (4/37), of HBV DNA was 36.4%(12/33) and 5.9% (1/17) in therapy and control groups respectively. There was obvious difference in two groups. The results suggest that IFN-alpha N1 is satisfying antiviral drug for CHB patients or patients non-responsive to other IFNs.
Liu
D
D
Beijing You An Hospital, Beijing 100054.
Wen
X
X
Meng
Q
Q
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015163:Superinfection / Q000188:drug therapy*
D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha